Copy to clipboard 
Kuros Biosciences announced that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrollment in the PARTNER clinical trial, the first patient treated with MagnetOs Flex Matrix and reaching a total of 10,000 patients treated with MagnetOs worldwide.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “The truly significant progress of MagnetOs is underlined by these three major milestones. The PARTNER trial marks an important advance in Project Fusion, which aims to create an unprecedented combination of scientific, pre-clinical and clinical studies to validate MagnetOs as a quality and reasonably priced alternative to cell-based allografts, bone morphogenetic proteins and premium-priced synthetic bone grafts.”
PARTNER is the first of five Level 1 randomized controlled trials for MagnetOs to be fully enrolled and conducted under the umbrella research program known as Project Fusion, which compares MagnetOs to the gold standard of autograft bone. A total of 30 patients with leg pain and/or back pain, requiring up to three-level instrumented posterolateral lumbar fusion, were included in the study and an interim analysis will be performed once the first 15 patients have completed their Month 6 visit with available measurements for the endpoints.
The first patient was treated with MagnetOs Flex Matrix, which opens up an opportunity for the 62% of all US spine surgeons who routinely mix their bone graft of choice with bone marrow aspirate. MagnetOs Flex Matrix was mixed with autograft and used in a posterolateral fusion over the facets in a patient with degenerative disc disease. MagnetOs Flex Matrix is a new open matrix bone graft with a unique fibrillar and flexible structure that optimizes the effect of Kuros’ established NeedleGrip™ surface technology and is extremely convenient to use with strength and flexibility.
Reaching 10,000 patients globally is an important commercial milestone, following launch in the UK in 2017, the US in 2019 and Australia and several EU countries in 2021, demonstrating the proven technology of MagnetOs in the real world of clinical practice as well as in controlled trial environments.
Source: Kuros Biosciences
Kuros Biosciences announced that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrollment in the PARTNER clinical trial, the first patient treated with MagnetOs Flex Matrix and reaching a total of 10,000 patients treated with MagnetOs worldwide.
Joost de Bruijn, Chief...
Kuros Biosciences announced that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrollment in the PARTNER clinical trial, the first patient treated with MagnetOs Flex Matrix and reaching a total of 10,000 patients treated with MagnetOs worldwide.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “The truly significant progress of MagnetOs is underlined by these three major milestones. The PARTNER trial marks an important advance in Project Fusion, which aims to create an unprecedented combination of scientific, pre-clinical and clinical studies to validate MagnetOs as a quality and reasonably priced alternative to cell-based allografts, bone morphogenetic proteins and premium-priced synthetic bone grafts.”
PARTNER is the first of five Level 1 randomized controlled trials for MagnetOs to be fully enrolled and conducted under the umbrella research program known as Project Fusion, which compares MagnetOs to the gold standard of autograft bone. A total of 30 patients with leg pain and/or back pain, requiring up to three-level instrumented posterolateral lumbar fusion, were included in the study and an interim analysis will be performed once the first 15 patients have completed their Month 6 visit with available measurements for the endpoints.
The first patient was treated with MagnetOs Flex Matrix, which opens up an opportunity for the 62% of all US spine surgeons who routinely mix their bone graft of choice with bone marrow aspirate. MagnetOs Flex Matrix was mixed with autograft and used in a posterolateral fusion over the facets in a patient with degenerative disc disease. MagnetOs Flex Matrix is a new open matrix bone graft with a unique fibrillar and flexible structure that optimizes the effect of Kuros’ established NeedleGrip™ surface technology and is extremely convenient to use with strength and flexibility.
Reaching 10,000 patients globally is an important commercial milestone, following launch in the UK in 2017, the US in 2019 and Australia and several EU countries in 2021, demonstrating the proven technology of MagnetOs in the real world of clinical practice as well as in controlled trial environments.
Source: Kuros Biosciences
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
